Squamous cell carcinoma cases were enriched for 54 specific mutations compared to adenocarcinoma cases including several substitutions in PIK3CA, TP53, and NFE2L2 that had current clinical trials in NSCLC or had an approved therapy in another tumor type (Supplementary Table S2). Here, NFE2L2 is linked to non-small cell lung carcinoma.